 - Patients who were intolerant to Imatinib or second line TK inhibitor like :sunitinib. Intolerance at any dose andor duration, is defined as patients who did not progress on imatinib or sunitinib and have discontinued imatinib and or sunitinib therapy due to any Grade 3 adverse events that persist in spite of optimal supportive care. Patients with Grade 2 adverse events related to imatinib or sunitinib therapy, in spite of optimal supportive care measures, that persist for one month or that recurs for more than 3 times whether the dose is reduced or discontinued will also qualify patients as intolerant 